Related party transactions
On 17 April 2020, the members of the management board were offered new subscription rights under Subscription Right Plan 2020, subject to acceptance. The final number of accepted subscription rights under Subscription Right Plan 2020 was enacted by notary deed of 2 July 2020. Under Subscription Right Plan 2020, the subscription rights have an exercise term of eight years as of the date of the offer. The exercise price of the subscription rights is €168.42. Each subscription right gives the right to subscribe for one new Galapagos share. For all the beneficiaries, the subscription rights vest only and fully on the first day of the fourth calendar year following the calendar year in which the grant was made. The subscription rights are not transferable and can in principle not be exercised prior to 1 January 2024.
On 6 and 7 May 2020, the members of the management board were offered new restricted stock units (‘RSUs’), subject to acceptance. The RSUs are offered for no consideration. The members of the management board accepted all RSUs offered to them. Each RSU represents the right to receive, at Galapagos’ discretion, one Galapagos share or a payment in cash of an amount equivalent to the volume-weighted average price of the Galapagos share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The first RSU grant will vest in full three years after the offer date. The second RSU grant has a four-year vesting period, with 25% vesting each year and a first vesting date on 1 May 2021. For the members of the management board, any vesting prior to the third anniversary of the offer date will always give rise to a payment in cash rather than a delivery of shares. The RSUs are not transferable.
The table below sets forth the number of subscription rights accepted under Subscription Right Plan 2020 and the total number of RSUs accepted by each member of the management board during the first nine months of 2020:
Name |
Title |
Number of 2020 subscription rights accepted |
Number of 2020 RSUs accepted |
|---|---|---|---|
Onno van de Stolpe |
Chief Executive Officer |
85,000 |
18,317 |
Bart Filius |
Chief Operating Officer; Chief Financial Officer |
50,000 |
12,600 |
Piet Wigerinck |
Chief Scientific Officer |
40,000 |
12,080 |
Walid Abi-Saab |
Chief Medical Officer |
40,000 |
12,080 |
Andre Hoekema |
Chief Business Officer |
30,000 |
832 |
Michele Manto |
Chief Commercial Officer |
30,000 |
5,920 |
During the first nine months of 2020, there were no changes to related party transactions disclosed in the 2019 annual report that potentially had a material impact on the financials of the first nine months of 2020.